|
lexapro zoloft Score ³ 30; N=92) lexapro zoloft, mean changes in MADRS scores from baseline to endpoint were –22.4 and –20.4 for the Lexapro and Zoloft groups lexapro zoloft, respectively. Patients treated with Lexapro and Zoloft each experienced improvement in anxiety symptoms associated with depression lexapro zoloft, according to the Hamilton Rating Scale for Depression (HAM-D) Anxiety Subscale total score.Both Lexapro and Zoloft were well tolerated in the eight-week study. Overall lexapro zoloft, about 85 percent of patients in each group completed the study. Only two and four percent of patients discontinued due to adverse events with Lexapro and Zoloft lexapro zoloft, respectively. Adverse events occurring at an incidence of >10 percent wit lexapro zoloft.
lexapro zoloft H Lexapro or Zoloft lexapro zoloft, respectively lexapro zoloft, included ejaculation disorder (23% and 23%) lexapro zoloft, diarrhea (13% and 23%) lexapro zoloft, nausea (17% and 17%) lexapro zoloft, insomnia (14% and 17%) lexapro zoloft, libido decreased (10% and 14%) lexapro zoloft, upper respiratory tract infection (10% and 14%) lexapro zoloft, dry mouth (4% and 14%) lexapro zoloft, headache (13% and 10%) lexapro zoloft, and somnolence (12% and 6%).Study MethodologyTwo hundred twelve patients lexapro zoloft, 18 to 80 years of age with major depressive disorder (baseline MADRS score ³ 22) lexapro zoloft, participated in the double-blind study. Following a one-week lexapro zoloft, single-blind lexapro zoloft, placebo lead-in period lexapro zoloft, patients were randomized to receive either a fixed dose of 10 mg per day of Lexapro (N=104) or a flexible dose of 50 to 200 mg per day of Zoloft (N=108). If clinically indicated lexapro zoloft, Zoloft was increased in 50 mg increments each week lexapro zoloft, as recommended in the U.S. package insert. The dose could also be decreased due to tolerability concerns. The mean dose of Zoloft at week eight was 144 mg per day. The primary efficacy variable was the change in the MADRS total score from baseline to week eight. The HAM-D Anxiety Subscale was also administered at each visit.About Lexapro Lexapro is the newest and fastest-growing selective serotonin reuptake inhibitor (SSRI) and is prescribed for more than three million patients in the U.S. Lexapro was developed by isolating the therapeutically active portion of.
lexapro zoloft Ay of Zoloft (N=108). If clinically indicated lexapro zoloft, Zoloft was increased in 50 mg increments each week lexapro zoloft, as recommended in the U.S. package insert. The dose could also be decreased due to tolerability concerns. The mean dose of Zoloft at week eight was 144 mg per day. The primary efficacy variable was the change in the MADRS total score from baseline to week eight. The HAM-D Anxiety Subscale was also administered at each visit.About Lexapro Lexapro is the newest and fastest-growing selective serotonin reuptake inhibitor (SSRI) and is prescribed for more than three million patients in the U.S. Lexapro was developed by isolating the therapeutically active portion of .
lexapro zoloft 
lexapro zoloft | | | | | |
lexapro zoloft
|
